{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:51:40Z","timestamp":1795013500504,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with multiple myeloma, an incurable malignancy of plasma cells, frequently develop osteolytic bone lesions that severely impact quality of life and clinical outcomes. Eliglustat, a U.S. Food and Drug Administration-approved glucosylceramide synthase inhibitor, reduced osteoclast-driven bone loss in preclinical in vivo models of myeloma. In combination with zoledronic acid, a bisphosphonate that treats myeloma bone disease, eliglustat provided further protection from bone loss. Autophagic degradation of TRAF3, a key step for osteoclast differentiation, was inhibited by eliglustat as evidenced by TRAF3 lysosomal and cytoplasmic accumulation. Eliglustat blocked autophagy by altering glycosphingolipid composition whilst restoration of missing glycosphingolipids rescued autophagy markers and TRAF3 degradation thus restoring osteoclastogenesis in bone marrow cells from myeloma patients. This work delineates both the mechanism by which glucosylceramide synthase inhibition prevents autophagic degradation of TRAF3 to reduce osteoclastogenesis as well as highlighting the clinical translational potential of eliglustat for the treatment of myeloma bone disease.<\/jats:p>","DOI":"10.1038\/s41467-022-35358-3","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T01:02:31Z","timestamp":1671670951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-8588","authenticated-orcid":false,"given":"Houfu","family":"Leng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-6071","authenticated-orcid":false,"given":"Hanlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0301-5983","authenticated-orcid":false,"given":"Shuhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina J.","family":"Chavda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-154X","authenticated-orcid":false,"given":"Daria","family":"Galas-Filipowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hantao","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Ersek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1230-2586","authenticated-orcid":false,"given":"Emma V.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdinc","family":"Sezgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5546-9752","authenticated-orcid":false,"given":"Ana Victoria","family":"Lechuga-Vieco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qing","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6487-276X","authenticated-orcid":false,"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6979-955X","authenticated-orcid":false,"given":"Qing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1257-5659","authenticated-orcid":false,"given":"Claire M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-7995","authenticated-orcid":false,"given":"Anna Katharina","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6344-1677","authenticated-orcid":false,"given":"Nicole J.","family":"Horwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"35358_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7\u201330 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"35358_CR2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/leu.2014.295","volume":"29","author":"ST Lwin","year":"2015","unstructured":"Lwin, S. T., Olechnowicz, S. W., Fowler, J. A. & Edwards, C. M. Diet-induced obesity promotes a myeloma-like condition in vivo. Leukemia 29, 507\u2013510 (2015).","journal-title":"Leukemia"},{"key":"35358_CR3","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4065\/mcp.2010.0520","volume":"85","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar, S. V., Kyle, R. A. & Buadi, F. K. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin. Proc. 85, 945\u2013948 (2010).","journal-title":"Mayo Clin. Proc."},{"key":"35358_CR4","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412\u20133420 (2005).","journal-title":"J. Clin. Oncol."},{"key":"35358_CR5","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"E Terpos","year":"2003","unstructured":"Terpos, E. et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102, 1064\u20131069 (2003).","journal-title":"Blood"},{"key":"35358_CR6","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423\u20131437 (2013).","journal-title":"Nat. Med."},{"key":"35358_CR7","doi-asserted-by":"crossref","first-page":"44347","DOI":"10.1074\/jbc.M202009200","volume":"277","author":"AP Armstrong","year":"2002","unstructured":"Armstrong, A. P. et al. A RANK\/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J. Biol. Chem. 277, 44347\u201344356 (2002).","journal-title":"J. Biol. Chem."},{"key":"35358_CR8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1172\/JCI66947","volume":"124","author":"Y Xiu","year":"2014","unstructured":"Xiu, Y. et al. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. J. Clin. Invest. 124, 297\u2013310 (2014).","journal-title":"J. Clin. Invest"},{"key":"35358_CR9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey, D. L. et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401\u2013419 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"35358_CR10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrclinonc.2011.197","volume":"9","author":"JE Brown","year":"2012","unstructured":"Brown, J. E. & Coleman, R. E. Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat. Rev. Clin. Oncol. 9, 110\u2013118 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"35358_CR11","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1200\/JCO.2008.16.9300","volume":"26","author":"A Badros","year":"2008","unstructured":"Badros, A. et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J. Clin. Oncol. 26, 5904\u20135909 (2008).","journal-title":"J. Clin. Oncol."},{"key":"35358_CR12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","volume":"84","author":"KA Kennel","year":"2009","unstructured":"Kennel, K. A. & Drake, M. T. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin. Proc. 84, 632\u2013637 (2009).","journal-title":"Mayo Clin. Proc."},{"key":"35358_CR13","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41577-018-0095-2","volume":"19","author":"AJ Clarke","year":"2019","unstructured":"Clarke, A. J. & Simon, A. K. Autophagy in the renewal, differentiation and homeostasis of immune cells. Nat. Rev. Immunol. 19, 170\u2013183 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"35358_CR14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.arr.2015.08.004","volume":"24","author":"V Pierrefite-Carle","year":"2015","unstructured":"Pierrefite-Carle, V., Santucci-Darmanin, S., Breuil, V., Camuzard, O. & Carle, G. F. Autophagy in bone: Self-eating to stay in balance. Ageing Res. Rev. 24, 206\u2013217 (2015).","journal-title":"Ageing Res. Rev."},{"key":"35358_CR15","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/jcp.24646","volume":"229","author":"YH Chung","year":"2014","unstructured":"Chung, Y. H. et al. Beclin-1 is required for RANKL-induced osteoclast differentiation. J. Cell Physiol. 229, 1963\u20131971 (2014).","journal-title":"J. Cell Physiol."},{"key":"35358_CR16","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1136\/annrheumdis-2015-207240","volume":"75","author":"NY Lin","year":"2016","unstructured":"Lin, N. Y. et al. Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss. Ann. Rheum. Dis. 75, 1203\u20131210 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"35358_CR17","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.devcel.2011.08.016","volume":"21","author":"CJ DeSelm","year":"2011","unstructured":"DeSelm, C. J. et al. Autophagy proteins regulate the secretory component of osteoclastic bone resorption. Dev. Cell 21, 966\u2013974 (2011).","journal-title":"Dev. Cell"},{"key":"35358_CR18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nri2998","volume":"11","author":"H Hacker","year":"2011","unstructured":"Hacker, H., Tseng, P. H. & Karin, M. Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat. Rev. Immunol. 11, 457\u2013468 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"35358_CR19","volume":"8","author":"AC Newman","year":"2017","unstructured":"Newman, A. C., Kemp, A. J., Drabsch, Y., Behrends, C. & Wilkinson, S. Autophagy acts through TRAF3 and RELB to regulate gene expression via antagonism of SMAD proteins. Nat. Commun. 8, 1537 (2017).","journal-title":"Nat. Commun."},{"key":"35358_CR20","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/ni.1800","volume":"10","author":"TL Thurston","year":"2009","unstructured":"Thurston, T. L., Ryzhakov, G., Bloor, S., von Muhlinen, N. & Randow, F. The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria. Nat. Immunol. 10, 1215\u20131221 (2009).","journal-title":"Nat. Immunol."},{"key":"35358_CR21","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1172\/JCI59987","volume":"125","author":"A Ersek","year":"2015","unstructured":"Ersek, A. et al. Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease. J. Clin. Invest. 125, 2279\u20132292 (2015).","journal-title":"J. Clin. Invest."},{"key":"35358_CR22","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/mp200313e","volume":"8","author":"O Abian","year":"2011","unstructured":"Abian, O. et al. Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol. Pharm. 8, 2390\u20132397 (2011).","journal-title":"Mol. Pharm."},{"key":"35358_CR23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-011-9368-7","volume":"34","author":"N Belmatoug","year":"2011","unstructured":"Belmatoug, N. et al. Gastrointestinal disturbances and their management in miglustat-treated patients. J. Inherit. Metab. Dis. 34, 991\u20131001 (2011).","journal-title":"J. Inherit. Metab. Dis."},{"key":"35358_CR24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fendo.2012.00106","volume":"3","author":"A Ersek","year":"2012","unstructured":"Ersek, A., Karadimitris, A. & Horwood, N. J. Effect of glycosphingolipids on osteoclastogenesis and osteolytic bone diseases. Front. Endocrinol. (Lausanne) 3, 106 (2012).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"35358_CR25","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s40265-014-0296-3","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole, R. M. Eliglustat: first global approval. Drugs 74, 1829\u20131836 (2014).","journal-title":"Drugs"},{"key":"35358_CR26","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00256-014-1891-9","volume":"43","author":"RS Kamath","year":"2014","unstructured":"Kamath, R. S. et al. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skelet. Radiol. 43, 1353\u20131360 (2014).","journal-title":"Skelet. Radiol."},{"key":"35358_CR27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/GIM.0b013e318195e2b6","volume":"11","author":"BE Rosenbloom","year":"2009","unstructured":"Rosenbloom, B. E., Becker, P. & Weinreb, N. Multiple myeloma and Gaucher genes. Genet Med. 11, 134 (2009).","journal-title":"Genet Med."},{"key":"35358_CR28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","volume":"374","author":"S Nair","year":"2016","unstructured":"Nair, S. et al. Clonal immunoglobulin against lysolipids in the origin of myeloma. N. Engl. J. Med. 374, 555\u2013561 (2016).","journal-title":"N. Engl. J. Med."},{"key":"35358_CR29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4452","volume":"235","author":"EV Pavlova","year":"2015","unstructured":"Pavlova, E. V. et al. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J. Pathol. 235, 113\u2013124 (2015).","journal-title":"J. Pathol."},{"key":"35358_CR30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1359\/JBMR.051007","volume":"21","author":"C Jacquin","year":"2006","unstructured":"Jacquin, C., Gran, D. E., Lee, S. K., Lorenzo, J. A. & Aguila, H. L. Identification of multiple osteoclast precursor populations in murine bone marrow. J. Bone Min. Res. 21, 67\u201377 (2006).","journal-title":"J. Bone Min. Res."},{"key":"35358_CR31","doi-asserted-by":"crossref","unstructured":"Gaudio, A. et al. Hematological diseases and osteoporosis. Int. J. Mol. Sci. 21, 3538 (2020).","DOI":"10.3390\/ijms21103538"},{"key":"35358_CR32","doi-asserted-by":"crossref","first-page":"101541","DOI":"10.1016\/j.beem.2021.101541","volume":"35","author":"EV Morris","year":"2021","unstructured":"Morris, E. V. & Edwards, C. M. Myeloma and marrow adiposity: unanswered questions and future directions. Best. Pract. Res. Clin. Endocrinol. Metab. 35, 101541 (2021).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"35358_CR33","doi-asserted-by":"crossref","unstructured":"Muruganandan, S., Ionescu, A. M. & Sinal, C. J. At the crossroads of the adipocyte and osteoclast differentiation programs: future therapeutic perspectives. Int. J. Mol. Sci. 21, 2277 (2020).","DOI":"10.3390\/ijms21072277"},{"key":"35358_CR34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-12-411619-1.00007-0","volume":"537","author":"EL Scheller","year":"2014","unstructured":"Scheller, E. L. et al. Use of osmium tetroxide staining with microcomputerized tomography to visualize and quantify bone marrow adipose tissue in vivo. Methods Enzymol. 537, 123\u2013139 (2014).","journal-title":"Methods Enzymol."},{"key":"35358_CR35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.coph.2015.05.005","volume":"22","author":"RG Russell","year":"2015","unstructured":"Russell, R. G. Pharmacological diversity among drugs that inhibit bone resorption. Curr. Opin. Pharm. 22, 115\u2013130 (2015).","journal-title":"Curr. Opin. Pharm."},{"key":"35358_CR36","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jcp.21787","volume":"220","author":"E Ang","year":"2009","unstructured":"Ang, E. et al. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades. J. Cell Physiol. 220, 450\u2013459 (2009).","journal-title":"J. Cell Physiol."},{"key":"35358_CR37","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/ni.2065","volume":"12","author":"A Oeckinghaus","year":"2011","unstructured":"Oeckinghaus, A., Hayden, M. S. & Ghosh, S. Crosstalk in NF-kappaB signaling pathways. Nat. Immunol. 12, 695\u2013708 (2011).","journal-title":"Nat. Immunol."},{"key":"35358_CR38","doi-asserted-by":"crossref","unstructured":"Boyce, B. F., Li, J., Xing, L. & Yao, Z. Bone remodeling and the role of TRAF3 in osteoclastic bone resorption. Front. Immunol. 9, 2263 (2018).","DOI":"10.3389\/fimmu.2018.02263"},{"key":"35358_CR39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3803\/EnM.2015.30.1.35","volume":"30","author":"BF Boyce","year":"2015","unstructured":"Boyce, B. F., Xiu, Y., Li, J., Xing, L. & Yao, Z. NF-\u03baB-mediated regulation of osteoclastogenesis. Endocrinol. Metab. 30, 35\u201344 (2015).","journal-title":"Endocrinol. Metab."},{"key":"35358_CR40","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbrc.2005.05.098","volume":"333","author":"I Zavrski","year":"2005","unstructured":"Zavrski, I. et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem. Biophys. Res. Commun. 333, 200\u2013205 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"35358_CR41","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.7150\/ijbs.12296","volume":"11","author":"X Kong","year":"2015","unstructured":"Kong, X. et al. Triterpenoid saponin W3 from anemone flaccida suppresses osteoclast differentiation through inhibiting activation of MAPKs and NF-kappaB pathways. Int. J. Biol. Sci. 11, 1204\u20131214 (2015).","journal-title":"Int. J. Biol. Sci."},{"key":"35358_CR42","doi-asserted-by":"crossref","first-page":"105644","DOI":"10.1016\/j.biocel.2019.105644","volume":"118","author":"FY Khusbu","year":"2020","unstructured":"Khusbu, F. Y. et al. Resveratrol induces depletion of TRAF6 and suppresses prostate cancer cell proliferation and migration. Int. J. Biochem. Cell Biol. 118, 105644 (2020).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"35358_CR43","doi-asserted-by":"crossref","first-page":"10928","DOI":"10.1128\/JVI.01365-16","volume":"90","author":"ST Chan","year":"2016","unstructured":"Chan, S. T., Lee, J., Narula, M. & Ou, J. J. Suppression of host innate immune response by hepatitis C virus via induction of autophagic degradation of TRAF6. J. Virol. 90, 10928\u201310935 (2016).","journal-title":"J. Virol."},{"key":"35358_CR44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1172\/JCI81655","volume":"126","author":"SM Hindi","year":"2016","unstructured":"Hindi, S. M. & Kumar, A. TRAF6 regulates satellite stem cell self-renewal and function during regenerative myogenesis. J. Clin. Invest. 126, 151\u2013168 (2016).","journal-title":"J. Clin. Invest."},{"key":"35358_CR45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13046-018-0760-0","volume":"37","author":"YH Wu","year":"2018","unstructured":"Wu, Y. H. et al. Bortezomib enhances radiosensitivity in oral cancer through inducing autophagy-mediated TRAF6 oncoprotein degradation. J. Exp. Clin. Cancer Res. 37, 91 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"35358_CR46","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14147","volume":"520","author":"J Diao","year":"2015","unstructured":"Diao, J. et al. ATG14 promotes membrane tethering and fusion of autophagosomes to endolysosomes. Nature 520, 563\u2013566 (2015).","journal-title":"Nature"},{"key":"35358_CR47","doi-asserted-by":"crossref","first-page":"580343","DOI":"10.3389\/fphar.2020.580343","volume":"11","author":"J Chicote","year":"2020","unstructured":"Chicote, J., Yuste, V. J., Boix, J. & Ribas, J. Cell death triggered by the autophagy inhibitory drug 3-methyladenine in growing conditions proceeds with DNA damage. Front. Pharm. 11, 580343 (2020).","journal-title":"Front. Pharm."},{"key":"35358_CR48","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.phrs.2016.01.028","volume":"105","author":"C Wang","year":"2016","unstructured":"Wang, C., Hu, Q. & Shen, H. M. Pharmacological inhibitors of autophagy as novel cancer therapeutic agents. Pharm. Res. 105, 164\u2013175 (2016).","journal-title":"Pharm. Res."},{"key":"35358_CR49","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1039\/D1BM00691F","volume":"9","author":"W Chen","year":"2021","unstructured":"Chen, W. et al. Autophagy inhibitors 3-MA and LY294002 repress osteoclastogenesis and titanium particle-stimulated osteolysis. Biomater. Sci. 9, 4922\u20134935 (2021).","journal-title":"Biomater. Sci."},{"key":"35358_CR50","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/jcb.25442","volume":"117","author":"S Zhu","year":"2016","unstructured":"Zhu, S. et al. Bafilomycin A1 attenuates osteoclast acidification and formation, accompanied by increased levels of SQSTM1\/p62 protein. J. Cell Biochem. 117, 1464\u20131470 (2016).","journal-title":"J. Cell Biochem."},{"key":"35358_CR51","doi-asserted-by":"crossref","first-page":"750","DOI":"10.4161\/auto.27959","volume":"10","author":"P Matarrese","year":"2014","unstructured":"Matarrese, P. et al. Evidence for the involvement of GD3 ganglioside in autophagosome formation and maturation. Autophagy 10, 750\u2013765 (2014).","journal-title":"Autophagy"},{"key":"35358_CR52","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.bpj.2017.06.050","volume":"113","author":"E Sezgin","year":"2017","unstructured":"Sezgin, E. et al. Polarity-sensitive probes for superresolution stimulated emission depletion microscopy. Biophys. J. 113, 1321\u20131330 (2017).","journal-title":"Biophys. J."},{"key":"35358_CR53","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17645-z","volume":"11","author":"J Vykoukal","year":"2020","unstructured":"Vykoukal, J. et al. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nat. Commun. 11, 4279 (2020).","journal-title":"Nat. Commun."},{"key":"35358_CR54","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","volume":"129","author":"MM McDonald","year":"2017","unstructured":"McDonald, M. M. et al. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood 129, 3452\u20133464 (2017).","journal-title":"Blood"},{"key":"35358_CR55","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrm.2017.16","volume":"18","author":"E Sezgin","year":"2017","unstructured":"Sezgin, E., Levental, I., Mayor, S. & Eggeling, C. The mystery of membrane organization: composition, regulation and roles of lipid rafts. Nat. Rev. Mol. Cell Biol. 18, 361\u2013374 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"35358_CR56","doi-asserted-by":"crossref","first-page":"18573","DOI":"10.1074\/jbc.M212626200","volume":"278","author":"H Ha","year":"2003","unstructured":"Ha, H. et al. Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. J. Biol. Chem. 278, 18573\u201318580 (2003).","journal-title":"J. Biol. Chem."},{"key":"35358_CR57","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1128\/JVI.02519-12","volume":"87","author":"DG Meckes Jr.","year":"2013","unstructured":"Meckes, D. G. Jr., Menaker, N. F. & Raab-Traub, N. Epstein-Barr virus LMP1 modulates lipid raft microdomains and the vimentin cytoskeleton for signal transduction and transformation. J. Virol. 87, 1301\u20131311 (2013).","journal-title":"J. Virol."},{"key":"35358_CR58","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1073\/pnas.081075298","volume":"98","author":"M Higuchi","year":"2001","unstructured":"Higuchi, M., Izumi, K. M. & Kieff, E. Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Proc. Natl Acad. Sci. USA 98, 4675\u20134680 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"35358_CR59","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ijc.20503","volume":"113","author":"H Ardila-Osorio","year":"2005","unstructured":"Ardila-Osorio, H. et al. TRAF interactions with raft-like buoyant complexes, better than TRAF rates of degradation, differentiate signaling by CD40 and EBV latent membrane protein 1. Int. J. Cancer 113, 267\u2013275 (2005).","journal-title":"Int. J. Cancer"},{"key":"35358_CR60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50761-5","volume":"9","author":"C Bedia","year":"2019","unstructured":"Bedia, C. et al. GM2-GM3 gangliosides ratio is dependent on GRP94 through down-regulation of GM2-AP cofactor in brain metastasis cells. Sci. Rep. 9, 14241 (2019).","journal-title":"Sci. Rep."},{"key":"35358_CR61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41580-019-0185-4","volume":"21","author":"A Ballabio","year":"2020","unstructured":"Ballabio, A. & Bonifacino, J. S. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat. Rev. Mol. Cell Biol. 21, 101\u2013118 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"35358_CR62","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2353\/ajpath.2009.080680","volume":"174","author":"J Wei","year":"2009","unstructured":"Wei, J. et al. Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies. Am. J. Pathol. 174, 1891\u20131909 (2009).","journal-title":"Am. J. Pathol."},{"key":"35358_CR63","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1002\/art.20637","volume":"50","author":"CK Lee","year":"2004","unstructured":"Lee, C. K. et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum. 50, 3831\u20133843 (2004).","journal-title":"Arthritis Rheum."},{"key":"35358_CR64","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.4161\/auto.29264","volume":"10","author":"DT Vogl","year":"2014","unstructured":"Vogl, D. T. et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed\/refractory myeloma. Autophagy 10, 1380\u20131390 (2014).","journal-title":"Autophagy"},{"key":"35358_CR65","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4161\/auto.29118","volume":"10","author":"R Rangwala","year":"2014","unstructured":"Rangwala, R. et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10, 1369\u20131379 (2014).","journal-title":"Autophagy"},{"key":"35358_CR66","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10495-015-1092-6","volume":"20","author":"C Garcia-Ruiz","year":"2015","unstructured":"Garcia-Ruiz, C., Morales, A. & Fernandez-Checa, J. C. Glycosphingolipids and cell death: one aim, many ways. Apoptosis 20, 607\u2013620 (2015).","journal-title":"Apoptosis"},{"key":"35358_CR67","doi-asserted-by":"crossref","unstructured":"Zhang, H. et al. Polyamines control eIF5A hypusination, TFEB translation, and autophagy to reverse B cell senescence. Mol. Cell 76, 110\u2013125 (2019).","DOI":"10.1016\/j.molcel.2019.08.005"},{"key":"35358_CR68","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/cphc.201402794","volume":"16","author":"E Sezgin","year":"2015","unstructured":"Sezgin, E., Waithe, D., Bernardino de la Serna, J. & Eggeling, C. Spectral imaging to measure heterogeneity in membrane lipid packing. Chemphyschem 16, 1387\u20131394 (2015).","journal-title":"Chemphyschem"},{"key":"35358_CR69","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/glycob\/cws061","volume":"22","author":"Z Wang","year":"2012","unstructured":"Wang, Z. et al. High expression of lactotriaosylceramide, a differentiation-associated glycosphingolipid, in the bone marrow of acute myeloid leukemia patients. Glycobiology 22, 930\u2013938 (2012).","journal-title":"Glycobiology"},{"key":"35358_CR70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/liv.12265","volume":"34","author":"J Zhu","year":"2014","unstructured":"Zhu, J. et al. Aberrant fucosylation of glycosphingolipids in human hepatocellular carcinoma tissues. Liver Int. 34, 147\u2013160 (2014).","journal-title":"Liver Int."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35358-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35358-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35358-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T12:38:25Z","timestamp":1739882305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35358-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["35358"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-35358-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-728824\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"17 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7868"}}